Clinical Trials List
2020-12-01 - 2024-01-30
Phase II
Recruiting5
Terminated1
ICD-10C53.9
Malignant neoplasm of cervix uteri, unspecified
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9180.9
Malignant neoplasm of cervix uteri, unspecified
-
-
Trial Applicant
-
Sponsor
-
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/05/14
Investigators and Locations
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 林建良 Division of Hematology & Oncology
- 高婉真 Division of Hematology & Oncology
- 陳昭勳 Division of Hematology & Oncology
- 陳彥勳 Division of Hematology & Oncology
- 曹朝榮 Division of Hematology & Oncology
- Shang-Wen Chen Division of Hematology & Oncology
- 黃文聰 Division of Hematology & Oncology
- 林正耀 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 沈書慧 Division of Radiology
- 張嘉珮 Division of Obstetrics & Gynecology
- Yen-Hou Chang Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 周宏學 Division of Obstetrics & Gynecology
- Ting-Chang Chang Division of Obstetrics & Gynecology
- 周宏學 Division of Obstetrics & Gynecology
- 黃寬仁 Division of Obstetrics & Gynecology
- Chyong-Huey Lai Division of Obstetrics & Gynecology
- Angel Chao Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 吳珮瑩 Division of Obstetrics & Gynecology
- 鄭雅敏 Division of Obstetrics & Gynecology
- Meng-Ru Shen Division of Obstetrics & Gynecology
- 梁玉玲 Division of Obstetrics & Gynecology
- Keng-Fu Hsu Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Recruiting
Study Contacts
- -
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
35 participants
-
Global
238 participants
